In addition, studies on kinases, which represent a well-studied class of cancer targets, have shown that while drug-resistant mutants of protein kinases have emerged for both allosteric and competitive compounds, to date no resistant mutations have been reported where an allosteric and an ATP-competitive inhibitors of a given kinase have been used in combination [24, 25]. The gene discussed is WEE1; the disease is cancer.